ArticleClinical and translational science2013
Different cellular localization of NF-κB p65 expression as an indicator of different prognoses of stage I-III gastric cancer patients.
Article in Clinical and translational science, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 6 citations in OpenAlex.
- CDK4/6-targeted therapy for gastrointestinal cancers: from resistance mechanisms to immuno-combination strategies guided by biomarkers.Frontiers in immunology · 2026Review
- The role of long non-coding RNA HCG18 in cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2023Review
- The positive regulatory loop of TCF4N/p65 promotes glioblastoma tumourigenesis and chemosensitivity.Clinical and translational medicine · 2022Article
- Long non-coding RNA HCG18 promotes gastric cancer progression by regulating miRNA-146a-5p/tumor necrosis factor receptor-associated factor 6 axis.Bioengineered · 2022Article
- NF-κB Signaling in Gastric Cancer.Toxins · 2017Review
- FOXO3-NF-κB RelA Protein Complexes Reduce Proinflammatory Cell Signaling and Function.Journal of immunology (Baltimore, Md. : 1950) · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNuclear factor-κB p65 (NF-κB p65) may play a significant role as a biomarker in tumor progression and metastasis. However, the correlation between cellular localization of NF-κB p65 expression and the prognosis of gastric cancer (GC) patients has not been studied. The present study was designed to investigate the location of NF-κB p65 expression in GC, and evaluate its correlation with clinicopathological parameters of GC patients.
methodsNF-κB p65 expressions in GC tissue and corresponding nonmalignant tissue from gastrectomy of 115 stage I-III GC patients were detected by immunohistochemistry. In addition, correlations between the staining results and the clinicopathologic features and survival of the GC patients were analyzed.
resultsThe percentage of NF-κB p65 expression in GC tissue and the corresponding nonmalignant tissue was 73.9% and 46.80%, respectively. No significant correlation was found between NF-κB p65 expression and the clinicopathologic parameters. Cox univariate analysis indicated that both nuclear staining and cytoplasmic staining of NF-κB p65 expression correlated with the prognosis of GC patients (log-rank, p = 0.0182; p = 0.0144, respectively).
conclusionHigh nuclear expression of NF-κB p65 is an independent prognostic marker predicting a better survival, while high cytoplasmic staining indicates a worse prognosis of GC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.